Cover Image

Variability in Liver Disease Progression and Outcomes in Glycogen Storage Disease Type IV

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Rebecca L. Koch, William R. Jeck, Priya S. Kishnani
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Hepatology Research
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biopsy‐Proven Reversal of F4 Cirrhosis in Classic Hepatic Glycogen Storage Disease Type IV: A 42‐Year Follow‐Up Without Transplantation
by: Masaaki Mino, et al.
Published: (2025)

Guidance for Liver Rehabilitation in Chronic Liver Disease
by: Shuji Terai, et al.
Published: (2026)

Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
by: Tsubasa Tsutsumi, et al.
Published: (2026)

Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders
by: Tsutomu Nishida, et al.
Published: (2026)

Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption
by: Jesse Pustjens, et al.
Published: (2025)

Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Oguzhan Celik, et al.
Published: (2026)

Digital Polymerase Chain Reaction‐Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease
by: Nomura Nao, et al.
Published: (2025)

Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease
by: Hideyuki Tamai, et al.
Published: (2025)

Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
by: Dong Wook Kim, et al.
Published: (2025)

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
by: Kazuya Kariyama, et al.
Published: (2026)

Response to the Letter “Steatotic Liver Disease and the ‘Point of No Return’ in the Development of Metabolic Disorders”
by: Yoshihiro Kamada
Published: (2026)

Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan
by: Yoshio Tokumoto, et al.
Published: (2025)

Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease
by: Atsushi Hiraoka, et al.
Published: (2025)

Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
by: Iulia Minciuna, et al.
Published: (2025)

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
by: Ryo Sato, et al.
Published: (2025)

Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study
by: Junichi Hanatani, et al.
Published: (2025)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026
by: Norio Akuta, et al.
Published: (2026)

Imaging‐Based Surveillance of Gastroesophageal Varices in Fontan‐Associated Liver Disease: Toward a Noninvasive Strategy
by: Tadashi Namisaki, et al.
Published: (2025)

Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
by: Tomomi Kogiso, et al.
Published: (2025)

Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy
by: Ming Lu, et al.
Published: (2025)

Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
by: Yoshihiro Kamada, et al.
Published: (2025)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
by: Takashi Motomura, et al.
Published: (2026)

Toward a Synthetic Data Revolution: Diffusion Model‐Enhanced Hepatocellular Carcinoma Prediction in Steatotic Liver Disease
by: Masaya Sato, et al.
Published: (2026)

The Impact of Inflammatory Markers on Prognosis in Advanced Chronic Liver Disease: Insights From a Prospective Cohort Study
by: Jing Liu, et al.
Published: (2025)

Association Between Liver Fibrosis and Cause‐Specific Mortality in Japanese Patients With Biopsy‐Confirmed Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD
by: Kyoko Sakai, et al.
Published: (2025)

Letter to the Editor: Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
by: Jianing Hou, et al.
Published: (2026)

Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
by: Ayumi Kanamoto, et al.
Published: (2026)

Response to the Letter “Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders”
by: Yoshihiro Kamada
Published: (2026)

The Nara Declaration: A New Collaborative Flow for Chronic Liver Disease Between Primary Care Physicians and Gastroenterologists/Hepatologists
by: Takumi Kawaguchi, et al.
Published: (2025)

Loss of Posterior Occlusal Support Is Associated With Incident Steatotic Liver Disease in a Nationwide Longitudinal Analysis of the JMDC Claims Database
by: Takashi Miyano, et al.
Published: (2026)

Post‐COVID‐19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan
by: Akira Uchiyama, et al.
Published: (2025)

Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
by: Motoh Iwasa, et al.
Published: (2025)

From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Wei‐Yue Lim, et al.
Published: (2026)

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
by: Kazuya Kariyama, et al.
Published: (2025)

Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
by: Kenji Imai, et al.
Published: (2025)

Response to “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
by: Kenji Imai, et al.
Published: (2026)

The 7S Domain of Type IV Collagen as a Noninvasive Surrogate of Portal Hypertension
by: Masayoshi Takami, et al.
Published: (2026)

Autoimmune Hepatitis Profiles After Liver Transplantation in Latin American Patients: A Cluster Analysis of Clinical Outcomes
by: Pedro Robson Costa Passos, et al.
Published: (2025)

Letter to the Editor: “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
by: Lixia Yao, et al.
Published: (2025)

Liver Transplantation in Japan: Registry by the Japanese Liver Transplantation Society
by: Koji Umeshita, et al.
Published: (2026)